Cardiovascular Risk Factors and LCH in Adults
|ClinicalTrials.gov Identifier: NCT00483925|
Recruitment Status : Unknown
Verified June 2007 by Laikon General District Hospital, Athens.
Recruitment status was: Recruiting
First Posted : June 8, 2007
Last Update Posted : June 8, 2007
Langerhans-cell histiocytosis (LCH) is a rare disease with features of chronic inflammation and hypopituitarism, conditions associated with increased risk of cardiovascular diseases.
Objective: To investigate glucose and lipid metabolism, insulin resistance, structural arterial and functional endothelial properties in patients with multisystem LCH in a prospective, observational study.
Interventions:Cardiovascular risk factors: arterial blood pressure, lipid profile, mathematical indices of insulin resistance (IR), intima media thickness, brachial artery flow mediated dilatation, dynamic indices of IR, pituitary function and C-reactive protein will be estimated in patients with LCH and in a control group matched for gender, age, BMI and smoking habits.
|Condition or disease|
Show Detailed Description
|Study Type :||Observational|
|Observational Model:||Case Control|
|Official Title:||CARDIOVASCULAR RISK FACTORS IN ADULT PATIENTS WITH MULTISYSTEM LANGERHANS-CELL HISTIOCYTOSIS: EVIDENCE OF GLUCOSE METABOLISM ABNORMALITIES|
|Study Start Date :||September 2005|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00483925
|Contact: Gregory Kaltsas, MD, FRCPfirstname.lastname@example.org|
|Division of Endocrinology, Department of Pathophysiology, Laiko University Hospital,||Recruiting|
|Athens, Greece, 11527|
|Contact: Gregory Kaltsas, MD, FRCP|
|Principal Investigator: Krystallenia I Alexandraki, MD, MSc, PhD|
|Study Director:||Gregory Kaltsas, MD, FRCP||Division of Endocrinology, Department of Pathophysiology, Laiko University Hospital|